UCB

Companies UCB

News UCB

• Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome

  The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutical acquir more

• Astellas and UCB announce approval of Cimzia in Japan for the treatment of rheumatoid arthritis

  Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous injection for more

• UCB and Proteros expand successful protein x-ray crystallography collaboration

  UCB and Proteros biostructures GmbH announced expansion of their ongoing structural biology collaboration to include additional therapeutic areas. Since 2007, Proteros has supported discovery programmes for UCB in the area of immunology, by solving complex unpublished protein structures to give UCB more

Publications UCB

• Effects of unconjugated bilirubin on chromosomal damage in individuals with Gilbert`s syndrome measured with the micronucleus cytome assay

  Circulating unconjugated bilirubin (UCB) has been reported to protect against lung and colorectal cancer. The present study aimed to explore, for the first time, whether mildly elevated circulating UCB, as found in Gilbert`s syndrome (GS), is associated with changes of DNA damage. A random 76 in more

• Mesenchymal stem cells promote a primitive phenotype CD34+c-kit+ in human cord blood-derived hematopoietic stem cells during ex vivo expansion

  The purpose of this study was to evaluate the influence of bone marrow-mesenchymal stem cells (BM-MSC) and exogenously added cytokines on the proliferation, primitive cell subpopulation maintenance (including the c-kit+ marker) and clonogenic capacity of hematopoietic stem cells (HSC). BM-MSC were c more

• Unconjugated Bilirubin Restricts Oligodendrocyte Differentiation and Axonal Myelination

  High levels of serum unconjugated bilirubin (UCB) in newborns are associated with axonal damage and glial reactivity that may contribute to subsequent neurologic injury and encephalopathy (kernicterus). Impairments in myelination and white matter damage were observed at autopsy in kernicteric infant more

Market studies UCB

• UCB S.A. – Product Pipeline Review – 2012

  Introduction Global Market Direct’s pharmaceuticals report, “UCB S.A. - Product Pipeline Review - 2012” provides data on the UCB S.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and more

• Global Biopharmaceuticals Market 2011-2015

  TechNavio's analysts forecast the Global Biopharmaceuticals market to grow at a CAGR of 4.9 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increased adoption of advanced technologies. The Global Biopharmaceuticals market has also been witnessing t more

• Global Central Nervous System Drugs Market 2011-2015

  TechNavio's analysts forecast the Global Central Nervous System Drugs market to grow at a CAGR of -3.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing size of aging population. The Global EEG/EMG Equipment market has also been witnessing more

Websites UCB